The estimated Net Worth of Ventures Iii, L.P.5 Am Part... is at least $23.7 Million dollars as of 27 June 2019. Ventures Part owns over 810,000 units of Arvinas Inc stock worth over $2,269,022 and over the last 5 years Ventures sold ARVN stock worth over $21,448,200.
Ventures has made over 2 trades of the Arvinas Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ventures sold 810,000 units of ARVN stock worth $17,714,700 on 27 June 2019.
The largest trade Ventures's ever made was selling 810,000 units of Arvinas Inc stock on 27 June 2019 worth over $17,714,700. On average, Ventures trades about 333,333 units every 7 days since 2019. As of 27 June 2019 Ventures still owns at least 91,162 units of Arvinas Inc stock.
You can see the complete history of Ventures Part stock trades at the bottom of the page.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe, and Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: